Global Acquired Autoimmune Hemolytic AnemiaMarket Insights Covering Revenue Trends And Future Growth Outlook

 

The Business Research Company’s 2026 market reports incorporate enhanced features, including market attractiveness scoring and analysis, total addressable market evaluation, a company scoring matrix, an interactive Excel data dashboard, refined supply chain analysis, insights on emerging startups, and overviews of key products, all aimed at improving the depth, usability, and strategic relevance of the insights delivered.
 
 What Increase In Market Value Is Expected For The Acquired Autoimmune Hemolytic Anemia Market By 2030?
 The acquired autoimmune hemolytic anemia market size has grown strongly in recent years. It will grow from $2.14 billion in 2025 to $2.29 billion in 2026 at a compound annual growth rate (CAGR) of 7.1%. The growth in the historic period can be attributed to improved autoimmune disease diagnosis, corticosteroid treatment reliance, hospital hematology specialization, increased malignancy-linked anemia cases, diagnostic test availability.
 
 The acquired autoimmune hemolytic anemia market size is expected to see strong growth in the next few years. It will grow to $3.01 billion in 2030 at a compound annual growth rate (CAGR) of 7.1%. The growth in the forecast period can be attributed to rare disease awareness growth, biologic therapy adoption, advanced diagnostic integration, hematology research funding, personalized treatment protocols. Major trends in the forecast period include increasing use of targeted immunosuppressive therapies, rising adoption of rituximab-based treatment, growth in hospital-based hematology care, improved diagnostic testing adoption, expansion of rare disease treatment programs.
 
 Download Your Free Report Sample:
 https://www.thebusinessresearchcompany.com/sample.aspx?id=24132&type=smp
  
 Which Factors Are Expected To Fuel The Acquired Autoimmune Hemolytic Anemia Market In The Coming Years?
 The increasing prevalence of autoimmune disorders is expected to propel the growth of the acquired autoimmune hemolytic anemia market going forward. Autoimmune disorders are when the body’s own healthy cells and tissues are wrongly attacked by the immune system because it believes they are dangerous invaders. The rising prevalence of autoimmune disorders is largely attributed to increased environmental triggers and lifestyle changes that may disrupt immune system regulation. The rising prevalence of autoimmune disorders contributes to a higher incidence of acquired autoimmune hemolytic anemia, as individuals with autoimmune conditions are more likely to develop secondary AIHA due to immune system dysregulation. For instance, in 2023, according to the Gastro-Intestinal Epidemiology Consortium (CanGIEC), a Canada-based national network of researchers and clinicians, the prevalence of inflammatory bowel disease, estimated at 825 cases per 100,000 people. This prevalence is forecasted to rise by 2.44% annually, reaching 1,075 cases per 100,000 people by 2035. Therefore, the increasing prevalence of autoimmune disorders will drive the growth of the acquired autoimmune hemolytic anemia market. 
 
 Who Are The Leading Participants In The Acquired Autoimmune Hemolytic Anemia Market?
 The acquired autoimmune hemolytic anemia market covered in this report is segmented — 
 
 1) By Diagnosis Method: Complete Blood Count, Peripheral Blood Smear, Direct Coombs Test, Indirect Coombs Test
 2) By Treatment Type: Corticosteroids, Immunosuppressive Agents, Intravenous Immunoglobulin, Rituximab
 3) By Severity: Mild, Moderate, Severe
 4) By End User: Hospitals, Specialty Clinics, Research Institutions
 
 Subsegments:
 1) By Complete Blood Count: Hemoglobin Level, Hematocrit (HCT), Reticulocyte Count, White Blood Cell Count, Platelet Count
 2) By Peripheral Blood Smear: Spherocytes, Polychromasia, Schistocytes, Increased Reticulocyte Count
 3) By Direct Coombs Test: Immunoglobulin G Coombs Test, Immunoglobulin M Coombs Test, Complement Coombs Test
 4) By Indirect Coombs Test: Screening For Alloantibodies, Detection Of Sensitizing Antibodies, Crossmatch Testing
 
 Which Industry Trends Are Transforming The Acquired Autoimmune Hemolytic Anemia Market?
 Major companies operating in the acquired autoimmune hemolytic anemia market are focusing on advancements in targeted therapies, such as neonatal Fc receptor (FcRn) blockers, to improve treatment efficacy, enhance maternal-fetal outcomes, and provide more effective interventions for high-risk pregnancies complicated by severe hemolytic disease. An FcRn blocker is a therapeutic antibody designed to inhibit the neonatal Fc receptor, which is responsible for recycling immunoglobulin G (IgG) antibodies in the body, thereby reducing pathogenic antibody levels that cause red blood cell destruction and hemolytic complications in both maternal and fetal populations. For instance, in January 2025, Johnson & Johnson, a US-based pharmaceutical and healthcare company, received U.S. Food and Drug Administration (FDA) Breakthrough Therapy Designation for nipocalimab for the treatment of individuals at high risk for severe hemolytic disease of the fetus and newborn (HDFN). Nipocalimab works by selectively blocking the neonatal Fc receptor (FcRn), reducing maternal IgG antibody levels that cross the placenta and attack fetal red blood cells, thereby preventing severe hemolytic disease, reducing the need for intrauterine transfusions, and improving outcomes for at-risk pregnancies. Nipocalimab specifically targets FcRn-mediated IgG recycling without affecting other immune functions. 
 
 What Segments Are Covered In The Acquired Autoimmune Hemolytic Anemia Market Report?
 The acquired autoimmune hemolytic anemia market covered in this report is segmented — 
 
 1) By Diagnosis Method: Complete Blood Count, Peripheral Blood Smear, Direct Coombs Test, Indirect Coombs Test
 2) By Treatment Type: Corticosteroids, Immunosuppressive Agents, Intravenous Immunoglobulin, Rituximab
 3) By Severity: Mild, Moderate, Severe
 4) By End User: Hospitals, Specialty Clinics, Research Institutions
 
 Subsegments:
 1) By Complete Blood Count: Hemoglobin Level, Hematocrit (HCT), Reticulocyte Count, White Blood Cell Count, Platelet Count
 2) By Peripheral Blood Smear: Spherocytes, Polychromasia, Schistocytes, Increased Reticulocyte Count
 3) By Direct Coombs Test: Immunoglobulin G Coombs Test, Immunoglobulin M Coombs Test, Complement Coombs Test
 4) By Indirect Coombs Test: Screening For Alloantibodies, Detection Of Sensitizing Antibodies, Crossmatch Testing
 
 Explore the Complete Acquired Autoimmune Hemolytic Anemia Market Report:
 https://www.thebusinessresearchcompany.com/report/acquired-autoimmune-hemolytic-anemia-global-market-report
 
 Which Regions Are Likely To Dominate The Acquired Autoimmune Hemolytic Anemia Market During The Forecast Period?
 https://www.thebusinessresearchcompany.com/report/acquired-autoimmune-hemolytic-anemia-global-market-report
 
 Contact Us:
 
 The Business Research Company: https://thebusinessresearchcompany.com/ 
 Americas +1 310–496–7795
 Asia +44 7882 955267 & +91 8897263534
 Europe +44 7882 955267 
 Email: marketing@tbrc.info
 
 Follow Us On:
 
 LinkedIn: https://in.linkedin.com/company/the-business-research-company